Umeå biotech firm Vakona has secured funding from existing and new investors to advance its innovative acne treatment targeting skin microbiome imbalances. This financing will help complete product development and prepare for clinical trials, aided by academic collaboration.
Umeå-based pharmaceutical company Vakona has been given a capital injection of just over SEK 14 million from five investors to help it develop a new drug to treat acne.
Umeå-based pharmaceutical company Vakona has signed an agreement with French company GTP Tech to initiate the first manufacturing steps of its acne medicine. “Production is at a level of quality that enables the medicine to be used in human clinical trials. If all goes well the medicine should be on the market within five to seven years”, says Mats Strömqvist, CEO and Chairman of the Board of Vak
Three investors are backing Umeå-based pharmaceutical company Vakona with funding worth millions of SEK. “We are absolutely delighted and proud to have attracted this investment. It’s a reward for many years of hard work and takes us one step closer to clinical human trials”, says Gabriella Persson, CEO of Vakona.